Vivos Therapeutics (VVOS) Share-based Compensation (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Share-based Compensation for 8 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 110.19% year-over-year to $2.6 million in Q2 2026; TTM through Jun 2026 was $2.6 million, a 110.19% increase from a year earlier, with the FY2025 full-year figure at $2.8 million, down 20.0% from the prior year.
• Share-based Compensation was $2.6 million for Q2 2026 at Vivos Therapeutics, roughly flat from $2.6 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $7.5 million in Q2 2024 and troughed at $86000.0 in Q4 2025.
• A 5-year average of $2.0 million and a median of $1.9 million in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation plunged 93.1% in 2023 and surged 833.33% in 2025, its largest moves.
• Over 5 years, Share-based Compensation stood at $775000.0 in 2022, then slumped by 86.32% to $106000.0 in 2023, then declined by 10.38% to $95000.0 in 2024, then retreated by 9.47% to $86000.0 in 2025, then soared by 2923.26% to $2.6 million in 2026.
• The last three Share-based Compensation figures came in at $2.6 million (Q2 2026), $2.6 million (Q1 2026), and $86000.0 (Q4 2025), per Business Quant data.